Hanzlah Ahmed

Hanzlah Ahmed

Auto-generated profile, based on publicly available information

Hanzlah Ahmed

Department of Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2026 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
ABAbdul Basit
Abdul Basit
HAHanzlah Ahmed
Hanzlah Ahmed
RBRayan Babar
Rayan Babar
SSShireen Sana Saeed
Shireen Sana Saeed
TSTayyaba Aftab Siddiqui
Tayyaba Aftab Siddiqui
SCSubhash Chander
Subhash Chander

5 April 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
MKMukesh Kumar
Mukesh Kumar
SKSumet Kumar
Sumet Kumar
SASheikh Muhammad Ebtehaj Ali
Sheikh Muhammad Ebtehaj Ali
HQHadia Qazi
Hadia Qazi
AJArshia Arif Janjua
Arshia Arif Janjua
ACAayush Chaulagain
Aayush Chaulagain
Background: Type 2 diabetes mellitus (T2DM) affects over 500 million people worldwide, with traditional therapies often failing to maintain long‐term glycaemic control. Ecnoglutide, a novel long‐acting GLP‐1 receptor agonist, has emerged as a promising therapeutic option. This systematic review and meta‐analysis evaluated the efficacy and safety of ecnoglutide in adults with T2DM. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, ClinicalTrials.gov , and Google Scholar through September 2025. Randomized controlled trials comparing ecnoglutide with placebo or active comparators in adults with T2DM were included. Primary outcomes were changes in HbA1c and body weight. Secondary outcomes included fasting plasma glucose, insulin resistance markers, lipid profile, liver enzymes, and adverse events. Risk of bias was assessed using the Cochrane RoB‐2 tool. Meta‐analysis was performed using random‐effects models, with mean differences and risk ratios calculated at 95% confidence intervals. Results: Four RCTs comprising 1643 participants (1162 receiving ecnoglutide, 444 controls) were included. Ecnoglutide significantly reduced HbA1c (MD = −0.44, 95% CI −0.55 to −0.33, p < 0.00001), body weight (MD = −5.63, 95% CI −7.90 to −3.35, p < 0.01), and fasting plasma glucose (MD = −0.81, 95% CI −1.03 to −0.59, p < 0.00001). Improvements were observed in insulin sensitivity, lipid profile, and liver enzymes. Adverse events occurred more frequently with ecnoglutide (RR = 1.09, p < 0.01), although predominantly gastrointestinal and mild‐to‐moderate, with no significant differences in serious adverse events. Conclusions: Ecnoglutide demonstrates robust efficacy in glycaemic control, weight reduction, and cardiometabolic parameters with an acceptable safety profile in adults with T2DM, supporting its therapeutic potential as a next‐generation GLP‐1 receptor agonist.

29 July 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SKSumet Kumar
Sumet Kumar
AJArshia Arif Janjua
Arshia Arif Janjua
LKLaksh Kumar
Laksh Kumar
SASheikh Muhammad Ebtehaj Ali
Sheikh Muhammad Ebtehaj Ali
HAHanzlah Ahmed
Hanzlah Ahmed
ACAayush Chaulagain
Aayush Chaulagain
Background: Uncontrolled hypertension (UH), a severe form of hypertension, persists despite the use of three or more antihypertensive medications. Its growing prevalence, particularly in patients with comorbidities, necessitates novel therapeutic options. Lorundrostat, a selective aldosterone synthase inhibitor, presents a promising mechanism of action by directly reducing aldosterone synthesis while sparing cortisol production, potentially offering an effective and safer alternative to mineralocorticoid receptor antagonists. Objectives: Three randomized controlled trials (RCTs) comprising 1568 participants were included to evaluate the efficacy and safety of lorundrostat in adults with UH as a primary objective, with a decrease in diastolic blood pressure and the incidence of hyperkalemia, hypotension, and serious adverse events, including life-threatening conditions, hospitalization, significant disability, and events resulting in death, as secondary outcomes of the study. Methods: A systematic search of PubMed, Embase, ScienceDirect, Cochrane, and ClinicalTrials.gov up to July 2025 was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Included RCTs compared lorundrostat to placebo in adult patients with resistant/UH. Outcomes were pooled using a random-effects model. Meta-regression explored moderators, including age, BMI, and comorbidities. Results: Three RCTs ( n = 1568) met inclusion criteria. Lorundrostat significantly reduced systolic blood pressure [mean difference (MD) = –8.40 mmHg, 95% confidence interval (CI) (–9.81, –6.99), P < 0.00001, I 2 = 0%] and diastolic blood pressure [MD = –3.84 mmHg, 95% CI (–5.06, –2.63), P < 0.00001, I 2 = 0%]. Adverse events were more frequent in the lorundrostat group [risk ratio (RR) = 1.41], with notable risks of hypotension (RR = 3.10) and hyperkalemia (RR = 7.31), though serious adverse events were not significantly increased (RR = 1.28). Conclusion: Lorundrostat demonstrates significant antihypertensive efficacy and a manageable safety profile in UH patients. Larger, long-term trials are warranted to further validate its safety across broader populations and complete its efficacy profile, emphasizing the unknown long-term cardiovascular outcomes of the intervention.

7 October 2025 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
RBRayan Babar
Rayan Babar
MCMuhammad Hammad Chola
Muhammad Hammad Chola
HAHanzlah Ahmed
Hanzlah Ahmed